↓ Skip to main content

A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using…

Overview of attention for article published in Investigational New Drugs, September 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

patent
3 patents

Citations

dimensions_citation
139 Dimensions

Readers on

mendeley
51 Mendeley
Title
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
Published in
Investigational New Drugs, September 2007
DOI 10.1007/s10637-007-9085-0
Pubmed ID
Authors

Brigette Ma, Boon Cher Goh, Eng Huat Tan, Kwok Chi Lam, Ross Soo, Swan Swan Leong, Ling Zhi Wang, Frankie Mo, Anthony T. C. Chan, Benny Zee, Tony Mok

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Poland 2 4%
Austria 1 2%
Unknown 48 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 16%
Researcher 8 16%
Student > Doctoral Student 5 10%
Student > Master 5 10%
Student > Bachelor 4 8%
Other 9 18%
Unknown 12 24%
Readers by discipline Count As %
Chemistry 17 33%
Biochemistry, Genetics and Molecular Biology 6 12%
Medicine and Dentistry 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Agricultural and Biological Sciences 1 2%
Other 3 6%
Unknown 15 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2022.
All research outputs
#4,849,926
of 23,371,053 outputs
Outputs from Investigational New Drugs
#171
of 1,191 outputs
Outputs of similar age
#13,625
of 70,924 outputs
Outputs of similar age from Investigational New Drugs
#5
of 13 outputs
Altmetric has tracked 23,371,053 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,191 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 70,924 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.